Skip Nav

Clinical Guidelines Portal

Home > Guidelines > Perinatal Guidelines > Appendix B: Acronyms
Text Size

Updated Perinatal Guideline

Updates were made to the Perinatal Guideline on January 22, 2013 and January 29, 2012. For an explanation of the updates, please see the correction notice.

Search Search Help

Guideline Search

Type your search term(s) in the text box. Users can only search one guideline at a time. To search for an exact phrase, use quotation marks (i.e. "what to start"). To narrow your search, add additional relevant terms. If you are not finding what you need, try searching similar terms (i.e. perinatal OR pregnancy) to broaden your search.Close

Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

Appendix B: Acronyms

Printer-Friendly Files

3TC  lamivudine

ABC  abacavir
ACOG  American College of Obstetricians and Gynecologists
ALT  alanine aminotransferase
anti-HBc hepatitis B core antibody
anti-HBs hepatitis B surface antibody
AOR  adjusted odds ratio
AP  antepartum
ART  antiretroviral therapy
ARV  antiretroviral
AST  aspartate aminotransferase
ATV  atazanavir
ATV/r  atazanavir/ritonavir
AUC  area under the curve
AZT  zidovudine

BID  twice daily
BMI  body mass index

CBC  complete blood count
CDC  Centers for Disease Control and Prevention
CI  confidence interval
Cmax  maximum plasma concentration
Cmin  minimum plasma concentration
CNS  central nervous system
CVS  chorionic villus sampling
CYP  cytochrome P
CYP3A4  cytochrome P450 3A4

d4T  stavudine
ddI  didanosine
DMPA  depot medroxyprogesterone acetate
DRV  darunavir
DRV/r  darunavir/ritonavir
DSMB  Data and Safety Monitoring Board

EC  enteric coated
ECG  electrocardiogram
EFV  efavirenz
EMS  ethyl methane sulfonate
ETR  etravirine

FDA  Food and Drug Administration
FPV  fosamprenavir
FPV/r  fosamprenavir/ritonavir
FTC  emtricitabine

gp  glycoprotein

HAV  hepatitis A virus
HBIG  hepatitis B immune globulin
HBsAg  hepatitis B surface antigen
HBV  hepatitis B virus
HCV  hepatitis C virus
HELLP  hemolysis, elevated liver enzymes, and low platelets
HGC  hard gel capsule
HR  hazard ratio
HRSA  Health Resources and Services Administration

IC50  inhibitory concentration 50%
IDV  indinavir
IGF  insulin-like growth factor
IP  intrapartum
IQR  interquartile range
IRIS  immune reconstitution inflammatory syndrome
IUD  intrauterine device
IV  intravenous/intravenously

LPV/r  lopinavir/ritonavir

MAC  Mycobacterium avium complex
MACDP  Metropolitan Atlanta Congenital Defects Program
MIRIAD  Mother-Infant Rapid Intervention at Delivery (study)
MTCT  mother-to-child transmission
mtDNA  mitochondrial DNA
MVC  maraviroc

NFV  nelfinavir
NIH  National Institutes of Health
NNRTI non-nucleoside reverse transcriptase inhibitor/non-nucleoside analogue reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor/nucleoside analogue reverse transcriptase inhibitor
NtRTI  nucleotide analogue reverse transcriptase inhibitor
NVP  nevirapine

OC  oral contraceptive
OI  opportunistic infection
OR  odds ratio

PACTG  Pediatric AIDS Clinical Trials Group
PCP  Pneumocystis jirovecii pneumonia
PCR  polymerase chain reaction
PI  protease inhibitor
PK  pharmacokinetic
PMTCT  prevention of mother-to-child transmission
PP  postpartum
PPI  proton pump inhibitor
PrEP  pre-exposure prophylaxis
PTD  preterm delivery

RAL  raltegravir
RDS  respiratory distress syndrome
RPV  rilpivirine
RR  relative risk
RTV  ritonavir

sd  single dose
SQ  subcutaneous
SQV  saquinavir
SQV/r  saquinavir/ritonavir
STD  sexually transmitted disease

T20  enfuvirtide
TDF  tenofovir disoproxil fumarate
TDM    therapeutic drug monitoring
TID  three times daily
TPV  tipranavir
TPV/r  tipranavir/ritonavir

UGT  uridine diphosphate glucuronosyltransferase

WHO  World Health Organization
WITS  Women and Infants Transmission Study

ZDV  zidovudine